



US006696480B2

(12) **United States Patent**
Liao

(10) **Patent No.:** **US 6,696,480 B2**
(45) **Date of Patent:** **Feb. 24, 2004**

(54) **UPREGULATION OF TYPE III
ENDOTHELIAL CELL NITRIC OXIDE
SYNTHASE BY AGENTS THAT DISRUPT
ACTIN CYTOSKELETAL ORGANIZATION**

(75) Inventor: **James K. Liao**, Weston, MA (US)

(73) Assignee: **Brigham and Women's Hospital, Inc.**,
Boston, MA (US)

(*) Notice: Subject to any disclaimer, the term of this patent is extended or adjusted under 35 U.S.C. 154(b) by 0 days.

(21) Appl. No.: **10/144,669**

(22) Filed: **May 13, 2002**

(65) **Prior Publication Data**

US 2003/0013703 A1 Jan. 16, 2003

Related U.S. Application Data

(62) Division of application No. 09/115,387, filed on Jul. 14, 1998, now Pat. No. 6,423,751.

(51) **Int. Cl.⁷** **A61K 31/15; A61K 38/00;**
A61K 36/16; A01N 37/18

(52) **U.S. Cl.** **514/411; 514/443; 514/2;**
514/8; 514/44; 514/211.08; 514/218; 514/220;
514/253.04; 514/253.05; 514/253.06; 514/253.07;
514/279; 514/307; 514/309; 514/369; 514/565;
514/602; 514/603; 514/604; 514/640; 424/130.1;
424/142.1; 424/152.1; 424/172.1

(58) **Field of Search** **514/411, 443,**
514/2, 8, 44, 211.08, 218, 220, 253.04,
253.05, 253.06, 253.07, 279, 307, 309,
369, 565, 602, 603, 604, 640; 424/130.1,
142.1, 152.1, 172.1

(56) **References Cited**

U.S. PATENT DOCUMENTS

3,983,140 A	9/1976	Endo et al.
4,231,938 A	11/1980	Monaghan et al.
4,346,227 A	8/1982	Terahara et al.
4,351,844 A	9/1982	Patchett et al.
4,444,784 A	4/1984	Hoffman et al.
4,448,784 A	5/1984	Glamkowski et al.
4,450,171 A	5/1984	Hoffman et al.
4,499,289 A	2/1985	Baran et al.
4,613,610 A	9/1986	Wareing
4,678,783 A	7/1987	Hidaka et al.
4,686,237 A	8/1987	Anderson
4,739,073 A	4/1988	Kathawala
4,912,107 A	3/1990	Kleinschroth et al.
4,965,200 A	10/1990	Chen et al.
5,030,447 A	7/1991	Joshi et al.
5,084,482 A	1/1992	Hirsch et al.
5,116,870 A	5/1992	Smith et al.
5,135,935 A	8/1992	Alberts et al.
5,180,589 A	1/1993	Joshi et al.
5,273,995 A	12/1993	Roth
5,298,497 A	3/1994	Tschollar et al.
5,354,772 A	10/1994	Kathawala
5,470,832 A	11/1995	Gibbs et al.
5,475,029 A	12/1995	Bradfute et al.

5,514,696 A	5/1996	Murugesan et al.
5,519,035 A	5/1996	Maiese et al.
5,530,001 A	6/1996	Nakajima et al.
5,591,772 A	1/1997	Lane et al.
5,602,098 A	2/1997	Sebti et al.
5,612,359 A	3/1997	Murugesan
5,622,985 A	4/1997	Olukotun et al.
5,723,456 A	3/1998	Jirousek et al.
5,756,453 A	5/1998	Vedder et al.
5,786,326 A	* 7/1998	Horwitz 514/11
6,180,597 B1	1/2001	Liao
6,491,938 B2	* 12/2002	Kunz et al. 424/423

FOREIGN PATENT DOCUMENTS

EP	0 671 171 A1	9/1995
JP	09183797 A	7/1997
WO	WO 98/34626	8/1998

OTHER PUBLICATIONS

Blauw, G.J., et al., "Stroke, Statins, and Cholesterol: A Meta-Analysis of Randomized, Placebo-Controlled, Double-Blind Trials With HMG-CoA Reductase Inhibitors" *Stroke* 28(5):946-950 (1997).

Boston Globe "Statins Found to Cut Risk of Stroke: Cholesterol Drugs Curbed Death Rate" (Jul. 23, 1997).

Bult, H., "Nitric Oxide and Atherosclerosis: Possible Implications for Therapy" *Mol. Med. Today* 2(12):510-518 (1996), Abstract.

Byington, R.P., et al., "Reduction in Cardiovascular Events During Pravastatin Therapy: Pooled Analysis of Clinical Events of the Pravastatin Atherosclerosis Intervention Program" *Circulation* 92(9):2419-2425 (1995).

Casino, P.R., et al., "The Role of Nitric Oxide in Endothelium-Dependent Vasodilation of Hypercholesterolemic Patients" *Circulation* 88(6):2541-2547 (1993), Abstract.

Cooke, J.P., et al., "Nitric Oxide Synthase: Role in the Genesis of Vascular Disease" *Annu. Rev. Med.* 48:489-509 (1997), Abstract.

(List continued on next page.)

Primary Examiner—Frederick Krass

(74) **Attorney, Agent, or Firm—Wolf, Greenfield & Sacks, P.C.**

(57) **ABSTRACT**

A use for agents that disrupt actin cytoskeletal organization is provided. In the instant invention, agents that disrupt actin cytoskeletal organization are found to upregulate endothelial cell Nitric Oxide Synthase activity. As a result, agents that disrupt actin cytoskeletal organization are useful in treating or preventing conditions that result from the abnormally low expression and/or activity of endothelial cell Nitric Oxide Synthase. Such conditions include hypoxia-induced conditions. Subjects thought to benefit mostly from such treatments include nonhyperlipidemics and nonhypercholesterolemics, but not necessarily exclude hyperlipidemics and hypercholesterolemics.

10 Claims, 6 Drawing Sheets